Ranbaxy recalls nearly 30,000 packs of allergy-relief drug in U.S.
Send a link to a friend
[May 02, 2014]
sUMBAI (Reuters) — Indian
drugmaker Ranbaxy Laboratories Ltd started recalling 29,790 packs of
an allergy-relief medicine in the United States in February, after
finding defects in the packaging, the U.S. Food and Drug
The loratadine and pseudoephedrine sulphate extended
release tablets being recalled carry an expiry date of September
2015, and were manufactured by Ranbaxy's Ohm Labs plant in New
Jersey, which is the company's only facility making generics for the
United States. (http://r.reuters.com/nuk98v)
All other Ranbaxy plants, based in India, have been banned from
exporting generics to the United States after the FDA found
manufacturing quality glitches that the agency believed could
compromise the quality of medicines.
Rival Indian drugmaker Sun Pharmaceutical Industries Ltd agreed to
buy Ranbaxy last month in a $3.2 billion deal, betting it can fix
The FDA classified the recall by Ohm Labs as Class II, which means
use of or exposure to the recalled products may cause temporary or
medically reversible adverse health consequences.
[to top of second column]
Ranbaxy did not immediately respond to requests for comment.
(Reporting by Zeba Siddiqui in Mumbai; editing by Subhranshu Sahu)
[© 2014 Thomson Reuters. All rights
Copyright 2014 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.